Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform

Published on :

Maryland Biotech Just Raised $85 Million to Begin Clinicals for its Intelligent Cell Therapy Platform With new funding, Arcellx furthers its cell therapy platform intended to address new therapies in oncology and autoimmune disease October 3, 2019 Arcellx, a privately-held biopharmaceutical company, today announced that it has raised $85 million in an oversubscribed Series B [….]